Navigation Links
Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians
Date:11/9/2011

MIAMI BEACH, Fla., Nov. 9, 2011 /PRNewswire/ -- Biotech developer Divine Skin Inc. (OTC Bulletin Board: DSKX) which has been expanding the topical hair-growth segment, is rolling out that market's newest, most potent, only customizable system, Polaris API Solution 9, to be supplied by physicians for treatment through multiple methods of action.

With well-established materials like minoxidil sulfate, finasteride, alfatradiol, and other active ingredients, Polaris API Solution 9 is the most complete solution that can be used for hair loss, either by prescription or over the counter configured to the individual needs of the patient by physicians. The current sales leader contains only 5% minoxidil in a standard carrier.

"We are launching a new category," declared CEO Daniel Khesin, speaking on a conference call with investors. "We expect this line to change the game and to offer a powerful new tool for dermatologists that can really make a difference in their approach to treatment."

Half of all men will experience some hair loss by age 50, and they can only purchase the customized Polaris product through physicians, who can create the potent mix of active pharmaceutical ingredients (API).

Divine Skin, which posted revenue of $5.4 million in 2010 — up 55 percent over the previous year — creates a major new revenue stream with Polaris API Solution 9, and stockholders expect to benefit for several years.

In published clinical trials, each major component of the new API — minoxidil sulfate, finasteride, and alfatradiol — has proven to inhibit androgenic alopecia (male pattern baldness) effectively. The system also includes other auxiliary agents like apple polyphenol, copper peptides, nutrients, and conditioners to enhance the formula further.

"With very few options available," says Khesin, "Polaris API Solution 9
'/>"/>

SOURCE Divine Skin Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Divine Skin Posts Record Sales for 2010: Up 55% Over 2009
2. Divine Skin Announces Four Deals for Explosive Distribution Growth
3. First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin
4. Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX)
5. Biotech Developer Divine Skin (DSKX) Debuts New Hair-Growth Molecule Nanoxidil
6. Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010
7. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
8. Rice rolls out new nanocars
9. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
10. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
11. Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Possible mold re-infestation in Guilemtte School ... a report from eagletribune.com posted May 14, 2013, the state ... result is positive, My Cleaning Products offered a tip ... , It was said in the Eagle Tribune report (5.14.13) ... campus sparked after a first-grade classroom was closed due to ...
(Date:5/20/2013)... 2013 , Collaboration with ... (ARS) in treatment of mastitis , ... Trials to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will ... Research Service (ARS) to develop and trial products targeting ...
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific Shore ... based products across a broad range of product ... retained investor relations firm, BlueWater Advisory Group, to ... to trading process, and to direct the company,s ... Matthew Mills , ...
(Date:5/20/2013)... N.C. , May 20, 2013 ... focused on developing differentiated antibiotics to meet critical ... today announced that it presented data at the ... Philadelphia demonstrating the antibacterial ... in Cempra,s prior Phase 2 clinical trial in ...
Breaking Biology Technology:Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3Phosphagenics Signs Research Agreement with the Agricultural Research Service 2Pacific Shore Holdings Retains Investor Relations Firm 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2
... strain of virus broadens government readiness program -, ... the vaccines division of sanofi-aventis Group, announced,today that the ... H5N1 bulk vaccine antigen to produce approximately 38.5 million,doses ... avian influenza. Sanofi,Pasteur has a multi- year contract with ...
... CHINA, April 28 Simcere,Pharmaceutical Group (NYSE: ... generic pharmaceuticals and manufacturer of the patented,anti-cancer biotech ... has been,informed that one of its existing shareholders, ... beneficially owned by 15,individuals, including certain senior management ...
... 28 MBF Healthcare,Acquisition Corp. (Amex: MBH ... today that it and Critical Homecare,Solutions Holdings, Inc. ... therapy and specialty infusion services, are,scheduled to present ... Annual Deutsche,Bank Healthcare Conference in Boston, MA. On ...
Cached Biology Technology:U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 2U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 3U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 4Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 3MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference 3
(Date:5/19/2013)... Researchers have engineered a strain of electricity-producing bacteria that ... donor and carbon dioxide as its sole source of ... report their findings at the 113th General Meeting of ... first result of current production solely on hydrogen," says ... with his co-authors are part of the Lovley Lab ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... Bethesda, MD (May 18, 2013) The AGA Research ... research into the relationship between the gut microbiota, one ... health and disease. , The AGA Research Awards ... colleagues from Massachusetts General Hospital and Harvard Medical School, ... Award recipient. Dr. Chan will receive $25,000 of funding, ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... Reportlinker.com announces that a new market research report is ... Markets: Microarrays and Lab-on-a-Chip http://www.reportlinker.com/p0170497/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html ... STUDY GOALS AND OBJECTIVES BCC,s ... of current and emerging biochip technologies and products, and ...
... of Escherichia coli causing a severe illness called hemolytic-uremic syndrome ... killed more than 20 people and sickened more than 2,000. ... strain of E. coli O104:H4 that produces a ... E. coli O157:H7. Two isolates from this outbreak ...
... Ore. June 6, 2011. Sustainability is the theme for ... Society, scheduled to meet in Portland June 19 to ... others from academia, government, non-profit groups, and private industry ... products industry and share information about innovations in the ...
Cached Biology News:Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 5Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 6Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 7Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 8Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 9Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 10Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 11Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 12Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 13Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 14Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 15Two isolates from E. coli outbreak available 2
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...
... short years since publication of the best-selling ... acclaimed Protein Protocols Handbook, there have been ... In recognition of the level of attention ... of new methodologies directed to study them, ...
... silencing experiments often call for critical, ... Transfection Agent refines siRNA transfection protocols ... lipid-based formulation can be used to ... are subcultured without increased cytotoxicity. ...
Biology Products: